Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Diseases (5)
- Virus Diseases (5)
- Nanomedicine (4)
- Nanotechnology (4)
- Pharmaceutics and Drug Design (4)
-
- Pharmacy and Pharmaceutical Sciences (4)
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (3)
- Life Sciences (3)
- Medicinal and Pharmaceutical Chemistry (3)
- Organic Chemicals (3)
- Pharmacology (3)
- Pharmacology, Toxicology and Environmental Health (3)
- Therapeutics (3)
- Immunology and Infectious Disease (2)
- Other Immunology and Infectious Disease (2)
- Amino Acids, Peptides, and Proteins (1)
- Animal Experimentation and Research (1)
- Biology (1)
- Biotechnology (1)
- Carbohydrates (1)
- Chemistry (1)
- Heterocyclic Compounds (1)
- Infectious Disease (1)
- Integrative Biology (1)
- Macromolecular Substances (1)
- Medical Biotechnology (1)
- Medical Sciences (1)
- Keyword
-
- Prodrug (4)
- Nanomedicine (3)
- HIV (2)
- ART (1)
- Abacavir (1)
-
- BB2r (1)
- Bioimaging (1)
- Cabotegravir (1)
- Cancer (1)
- Chemical vaccine (1)
- Darunavir (1)
- Dolutegravir (1)
- Drug delivery (1)
- Epilepsy (1)
- Exosomes (1)
- GIRK 1/2 (1)
- HIV SPECT/CT THERANOSTICS ANTIRETROVIRAL PHARMACOKINETIC MODELING (1)
- HIV prevention and treatment (1)
- HIV-1 (1)
- Injectables (1)
- Kidney (1)
- LASER ART (1)
- Long-Acting (1)
- Long-acting (1)
- Long-acting formulation (1)
- Macrophage (1)
- MrgX1 (1)
- Nanoformulation (1)
- Nanoformulations (1)
- Pain (1)
Articles 1 - 9 of 9
Full-Text Articles in Pharmaceutical Preparations
Design And Synthesis Of Small Molecular Probes For Cns And Kidney Disorders, Swagat H. Sharma
Design And Synthesis Of Small Molecular Probes For Cns And Kidney Disorders, Swagat H. Sharma
Theses & Dissertations
The G protein regulated inwardly rectifying potassium channels (GIRK) are a family of inwardly rectifying potassium channels and are key effectors in signaling pathways. GIRK 1/2 channel subunit, predominantly found in the brain, is involved pathophysiology of various neurological disorders including, but not limited to, epilepsy, anxiety, Parkinson's, pain, reward, and addiction. Previously, our laboratory had identified a series of urea containing molecules as GIRK1/2 preferring activators. Unfortunately, the urea series suffers from significant PK liabilities (solubility, brain penetration and high clearance). The chapter 1 of the dissertation describes our efforts in developing three new series of activators with improved …
Development Of Once-A-Year Injectable Formulation Of Cabotegravir For Prevention And Treatment Of Hiv Infection, Tanmay Abhay Kulkarni
Development Of Once-A-Year Injectable Formulation Of Cabotegravir For Prevention And Treatment Of Hiv Infection, Tanmay Abhay Kulkarni
Theses & Dissertations
Long-acting cabotegravir (CAB) extends antiretroviral drug (ARV) dosing to monthly for maintenance of human immunodeficiency virus type one (HIV-1) suppression and to every other month for prevention of viral transmission. However, injection dose volumes, site reactions, and clinical oversights that are required remain obstacles towards broad usage. To meet these needs, surfactant coated hydrophobic and lipophilic CAB prodrugs were created with controlled prodrug dissolution, hydrolysis and drug tissue penetration. To such ends, fatty acid ester CAB nanocrystal prodrugs with 14, 18, and 22 added carbon chains were synthesized then nanoformulated as NMCAB, NM2CAB, and NM3CAB. These nanocrystal formulations were tested …
Development Of Long-Acting Antiviral Drug Nanoformulations, Denise Cobb
Development Of Long-Acting Antiviral Drug Nanoformulations, Denise Cobb
Theses & Dissertations
Antiretroviral therapy (ART) has improved the quality and duration of life for people living with human immunodeficiency virus (HIV) infection. However, opportunities to improve its profile abound. ART is limited by putative viral reservoir penetrance, emergence of viral mutations, inherent toxicities, and regimen non-adherence. These highlight the need improved drug delivery schemes. Previously, our lab has demonstrated that targeting mononuclear phagocytes for antiretroviral drug delivery extends drug half-life and improves penetrance into viral reservoirs, addressing these limitations of ART. Herein, we developed synthetic and biologic antiretroviral (ARV) drug nanocarriers improve the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of ARVs through …
Development Of Hyaluronic Acid-Derived Macromolecular Agents For Multimodal Imaging Probes And Nanomedicine, William M. Payne
Development Of Hyaluronic Acid-Derived Macromolecular Agents For Multimodal Imaging Probes And Nanomedicine, William M. Payne
Theses & Dissertations
Cancer, one of the most challenging maladies facing modern medicine, is a complex family of diseases that requires a multifaceted treatment regime. In recent years, increased research effort has been placed on the development of nanoscale formulations as a potential method to improve therapeutic efficacy and offer better treatment. Both drug formulation and biomedical imaging has benefitted from the development of new, nanoscale agents. Hyaluronic Acid (HA), a naturally occurring glycosaminoglycan, is a promising platform for the development of new drug delivery systems. Furthermore, hyaluronic acid is the principal ligand for the cell surface receptor CD44, which is overexpressed on …
Theranostics For Antiretroviral Biodistribution And Pharmacokinetics, Brendan M. Ottemann
Theranostics For Antiretroviral Biodistribution And Pharmacokinetics, Brendan M. Ottemann
Theses & Dissertations
RATIONALE: Our laboratories birthed the field of human immunodeficiency virus (HIV) theranostics. The new field allows simultaneous detection (diagnostics) and treatment (therapeutic) for the identification, treatment and inevitable elimination of virus in cell and tissue compartments. By employing theranostics, antiretroviral drugs (ARVs) can be tracked in lymph nodes, gut, spleen and liver. Cellular viral reservoirs including CD4+ T cell populations and mononuclear phagocytes (MP; monocytes, macrophages, microglia and dendritic cells) along with subcellular endosomal structures can now be targeted for drug delivery bringing therapeutics to areas where virus replicates. The overarching idea rests in improving precision targeted ARV delivery. …
Synthesis And Characterization Of Long Acting Darunavir Prodrugs, Mary Banoub
Synthesis And Characterization Of Long Acting Darunavir Prodrugs, Mary Banoub
Theses & Dissertations
Patient adherence is critical for ART success to ensure adequate viral suppression, therefore, long-acting antiretrovirals are soon replacing current daily regimens. In recent years, two drugs were successfully transformed into long-acting injectables; CAB LA and RPV LA. These long-acting nanoformulations made it possible to abandon the daily pill burden, instead approximately a bimonthly injection of both drugs is enough to suppress and maintain viral load suppression. Our laboratory has been instrumental in transforming FDA-approved and experimental-HIV medications into long-acting slow effective release drugs, also known as LASER ART. LASER ART consists of slow drug metabolism and high permeability and retention …
Development Of Approaches Of Tumor Trapping Enhanced Bb2r-Targeted Radiopharmaceuticals For Prostate Cancer, Wenting Zhang
Development Of Approaches Of Tumor Trapping Enhanced Bb2r-Targeted Radiopharmaceuticals For Prostate Cancer, Wenting Zhang
Theses & Dissertations
The Gastrin-Releasing Peptide Receptor (BB2r) has been intensively investigated as a cancer target over the years. Numerous diagnostic and therapeutic BB2r-targeted agents have been developed for various solid tumors, including prostate cancers, due to the high expression level of BB2r on neoplastic relative to normal tissues. The development of those targeted agents have mainly utilized the modified c-terminal of bombesin(BBN), a peptide that has nanomolar binding affinity to human BB2r. However, a major issue that hinders the clinical translational potential of low-molecular weight, receptor-targted agents, is their short residence time at tumor tissues due to the intrinsically high diffusion and …
Development Of A Long-Acting Nanoformulation Of Dolutegravir For Prevention And Treatment Of Hiv-1 Infection, Brady Sillman
Development Of A Long-Acting Nanoformulation Of Dolutegravir For Prevention And Treatment Of Hiv-1 Infection, Brady Sillman
Theses & Dissertations
Dolutegravir (DTG) is a potent human immunodeficiency virus type 1 (HIV-1) integrase strand-transfer inhibitor (INSTI) with a high barrier to viral drug resistance. However, opportunities to improve its profile abound. These include extending the drug’s apparent half-life, increasing penetrance to “putative” viral reservoirs, and reducing inherent toxicities. These highlight, in part, the need for long-acting, slow effective release antiretroviral therapy (LASER ART) delivery schemes. A long-acting (LA) DTG was made by synthesizing a hydrophobic and lipophilic prodrug encased with poloxamer (P407) surfactant. This modified DTG (MDTG) reduced systemic metabolism and polarity, increased lipophilicity and membrane permeability, improved encapsulation, and formed …
Synthesis And Development Of Long-Acting Abacavir Prodrug Nanoformulations, Dhirender Singh
Synthesis And Development Of Long-Acting Abacavir Prodrug Nanoformulations, Dhirender Singh
Theses & Dissertations
Over the past decade, work from our laboratory has demonstrated the potential of targeted nanoformulated antiretroviral therapy (nanoART) to produce sustained high plasma and tissue drug concentrations for weeks following a single intramuscular (IM) administration that can suppress ongoing viral replication and mitigate dose associated viral resistance. While progress has occurred towards developing long-acting nanoformulations for protease and nonnucleoside reverse transcriptase (RT) inhibitors, development of nanoformulations of hydrophilic nucleoside RT inhibitor drugs have remained elusive. Abacavir (ABC); a hydrophilic molecule exhibited limited utilities to develop into long-acting nanoformulation platform. Furthermore, inefficient conversion of ABC to its biological active metabolites; carbovir …